Nucletron Spotlights Innovations During ESTRO29

September 10, 2010

VEENENDAAL, The Netherlands, September 10, 2010 /PRNewswire/ –

– Exciting New Solutions for Precision Cancer Treatment on Display During
ESTRO29 in Barcelona, Spain

Nucletron, a leading provider of state of the art radiotherapy solutions
for cancer treatment, today announced a large number of exciting innovations
for precise cancer treatment that will be in the spotlight during ESTRO29 in
Barcelona. The company will be showcasing the latest developments in cancer
treatment solutions for both brachytherapy and external beam.

The complete program for prostate brachytherapy

Nucletron Prostate Solutions is the first complete program for prostate
brachytherapy, integrating state-of-the-art Oncentra software and high-class
brachytherapy equipment. Next to years of evidence confirming favorable cure
rates, these advanced solutions shorten overall treatment times, while
reducing risks of impotence and incontinence. Available for two treatment
types – Oncentra(R) Seeds for permanent low dose rate (LDR) seeds
implantation and Oncentra(R) Prostate for high dose rate (HDR) – it offers
the best choice of treatment for many prostate cancer patients.

Breast brachytherapy: See what you treat, treat what you see

AccuBoost(TM) is the first technology to use HDR brachytherapy treatment
of breast cancer in a non-invasive way, utilizing real-time mammography
imaging to accurately target the radiation dose directly to the lumpectomy
site. AccuBoost can be delivered either prior to or after the main external
beam portion of a woman’s breast irradiation treatment.

Pioneering developments in gynecological brachytherapy

Whether you use CT, MR or any other imaging modality, Nucletron can offer
a suitable applicator for gynecological brachytherapy. The newest in our
range of applicators are the Multichannel Vaginal Cylinder for asymmetrical
and advanced vaginal and cervical tumors, and the Rotterdam Cervix
Applicator, designed for fast and reproducible treatments. These two
applicators give ultimate precision in gynecological brachytherapy.

Optimal speed and precision in treatment planning

Oncentra(R) 4.0 is the newest version of Nucletron’s multi-modality
treatment planning system for brachytherapy and external beam treatment.
Oncentra v4.0 is the first ever platform to use GPU technology to increase
plan accuracy and reduce planning times from hours to minutes, especially for
VMAT calculations. New Oncentra Brachy features, such as applicator modeling,
library plans and output manager, are specially developed to make
brachytherapy treatment planning easier and faster.

Flexitron numbers talk

The Flexitron afterloader takes brachytherapy to a new level. It helps to
shorten preparation time and reduces the chance of human errors with its
straightforward Absolute Source Positioning. It sets a new safety benchmark,
with features like the precise source drive. It’s not just words, Flexitron’s
numbers talk and improve safety!

Visit Nucletron during ESTRO29 at booth 170 to find more information on
the latest innovations in precision cancer treatment, and to receive a demo.
Visit http://www.nucletron.com/estro29 for more information.

About Nucletron

Nucletron provides state of the art radiotherapy solutions for cancer
treatment that meet the evolving needs of patients, their caregivers and
healthcare professionals around the world. Nucletron has unmatched global
leadership in brachytherapy, a very precise, highly effective and
well-tolerated treatment option for healthcare providers, tailored to the
needs of individual patients. We work with clinical teams to constantly
improve and develop an innovative portfolio of integrated products, software
and services that assures excellent patient outcomes. Headquartered in
Veenendaal, The Netherlands, Nucletron employs more than 500 employees, with
offices in 15 countries, and products available in more than 100 countries
around the world. Please visit http://www.nucletron.com to learn more about
our healthcare solutions.


SOURCE Nucletron

Source: newswire

comments powered by Disqus